Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1779 (LINC01779) is classified as a long intergenic non-coding RNA (lincRNA) gene, defined as an autonomously transcribed non-coding RNA longer than 200 nucleotides that does not overlap annotated coding genes[1][3][5]. The function of LINC01779 specifically is not well characterized in the scientific literature, and no roles as a therapeutic target or disease biomarker are currently documented[1][3]. As with other lincRNAs, such transcripts may regulate neighboring genes, participate in chromatin remodeling, influence genome architecture, or have other context-dependent regulatory effects, but the functions of most lincRNAs—including LINC01779—remain to be fully elucidated[5]. There are currently no drugs known to interact with LINC01779, and it is not recognized as a therapeutic target or biomarker in clinical practice[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1779 (LINC01779).